Literature DB >> 26422501

Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration.

Cristian A Amador, Jean-Philippe Bertocchio, Gwennan Andre-Gregoire, Sandrine Placier, Jean-Paul Duong Van Huyen, Soumaya El Moghrabi, Stefan Berger, David G Warnock, Christos Chatziantoniou, Iris Z Jaffe, Philippe Rieu, Frederic Jaisser.   

Abstract

Calcineurin inhibitors such as cyclosporine A (CsA) are still commonly used after renal transplantation, despite CsA--induced nephrotoxicity (CIN), which is partly related to vasoactive mechanisms. The mineralocorticoid receptor (MR) is now recognized as a key player in the control of vascular tone, and both endothelial cell- and vascular smooth muscle cell (SMC)-MR modulate the vasoactive responses to vasodilators and vasoconstrictors. Here we tested whether vascular MR is involved in renal hemodynamic changes induced by CsA. The relative contribution of vascular MR in acute CsA treatment was evaluated using mouse models with targeted deletion of MR in endothelial cell or SMC. Results indicate that MR expressed in SMC, but not in endothelium, contributes to the increase of plasma urea and creatinine, the appearance of isometric tubular vacuolization, and overexpression of a kidney injury biomarker (neutrophil gelatinase--associated lipocalin) after CsA treatment. Inactivation of MR in SMC blunted CsA--induced phosphorylation of contractile proteins. Finally, the in vivo increase of renal vascular resistance induced by CsA was blunted when MR was deleted from SMC cells, and this was associated with decreased L-type Ca2D channel activity. Thus, our study provides new insights into the role of vascular MR in renal hemodynamics during acute CIN, and provides rationale for clinical studies of MR antagonism to manage the side effects of calcineurin inhibitors.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26422501      PMCID: PMC5034861          DOI: 10.1038/ki.2015.312

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  47 in total

1.  Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.

Authors:  Amandine Viau; Khalil El Karoui; Denise Laouari; Martine Burtin; Clément Nguyen; Kiyoshi Mori; Evangéline Pillebout; Thorsten Berger; Tak Wah Mak; Bertrand Knebelmann; Gérard Friedlander; Jonathan Barasch; Fabiola Terzi
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

Review 2.  Calcineurin inhibitor nephrotoxicity.

Authors:  Maarten Naesens; Dirk R J Kuypers; Minnie Sarwal
Journal:  Clin J Am Soc Nephrol       Date:  2009-02       Impact factor: 8.237

3.  The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure.

Authors:  Aurelie Nguyen Dinh Cat; Violaine Griol-Charhbili; Laurent Loufrani; Carlos Labat; Laura Benjamin; Nicolette Farman; Patrick Lacolley; Daniel Henrion; Frederic Jaisser
Journal:  FASEB J       Date:  2010-03-18       Impact factor: 5.191

Review 4.  Vascular mineralocorticoid receptor and blood pressure regulation.

Authors:  Antoine Tarjus; Cristian Amador; Luis Michea; Frédéric Jaisser
Journal:  Curr Opin Pharmacol       Date:  2015-02-28       Impact factor: 5.547

5.  RGS4 controls renal blood flow and inhibits cyclosporine-mediated nephrotoxicity.

Authors:  A Siedlecki; J R Anderson; X Jin; J R Garbow; T S Lupu; A J Muslin
Journal:  Am J Transplant       Date:  2009-12-02       Impact factor: 8.086

6.  The natural history of chronic allograft nephropathy.

Authors:  Brian J Nankivell; Richard J Borrows; Caroline L-S Fung; Philip J O'Connell; Richard D M Allen; Jeremy R Chapman
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

7.  Divergent effects of calcium channel and angiotensin converting enzyme blockade on glomerulotubular function in cyclosporine-treated renal allograft recipients.

Authors:  J J Sennesael; J G Lamote; I Violet; S Tasse; D L Verbeelen
Journal:  Am J Kidney Dis       Date:  1996-05       Impact factor: 8.860

Review 8.  New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone.

Authors:  Norma A Bobadilla; Gerardo Gamba
Journal:  Am J Physiol Renal Physiol       Date:  2007-04-11

9.  Oral cyclosporine but not tacrolimus reduces renal transplant blood flow.

Authors:  Brian J Nankivell; Jeremy R Chapman; George Bonovas; Simon M Gruenewald
Journal:  Transplantation       Date:  2004-05-15       Impact factor: 4.939

10.  Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors.

Authors:  Amy McCurley; Paulo W Pires; Shawn B Bender; Mark Aronovitz; Michelle J Zhao; Daniel Metzger; Pierre Chambon; Michael A Hill; Anne M Dorrance; Michael E Mendelsohn; Iris Z Jaffe
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

View more
  17 in total

1.  Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1.

Authors:  Jonatan Barrera-Chimal; Gwennan André-Grégoire; Aurelie Nguyen Dinh Cat; Sebastian M Lechner; Jérôme Cau; Sonia Prince; Peter Kolkhof; Gervaise Loirand; Vincent Sauzeau; Thierry Hauet; Frédéric Jaisser
Journal:  J Am Soc Nephrol       Date:  2017-01-13       Impact factor: 10.121

Review 2.  30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature.

Authors:  Jennifer J DuPont; Iris Z Jaffe
Journal:  J Endocrinol       Date:  2017-07       Impact factor: 4.286

3.  Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.

Authors:  Mara Medeiros; Luis Velásquez-Jones; Ana M Hernández; Guillermo Ramón-García; Saúl Valverde; Yolanda Fuentes; Arindal Vargas; Mauricio Patiño; Rosalba Pérez-Villalva; Juan Antonio Ortega-Trejo; Jonatan Barrera-Chimal; Norma A Bobadilla
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-23       Impact factor: 8.237

Review 4.  The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease.

Authors:  M Elizabeth Moss; Brigett Carvajal; Iris Z Jaffe
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

Review 5.  Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease.

Authors:  Toshifumi Nakamura; Sophie Girerd; Frederic Jaisser; Jonatan Barrera-Chimal
Journal:  Kidney Int Suppl (2011)       Date:  2022-03-18

Review 6.  The Role of the Mineralocorticoid Receptor in Inflammation: Focus on Kidney and Vasculature.

Authors:  Zachary Belden; Jeffrey A Deiuliis; Mirela Dobre; Sanjay Rajagopalan
Journal:  Am J Nephrol       Date:  2017-10-10       Impact factor: 3.754

Review 7.  Vascular Mineralocorticoid Receptor: Evolutionary Mediator of Wound Healing Turned Harmful by Our Modern Lifestyle.

Authors:  Lauren A Biwer; Mary C Wallingford; Iris Z Jaffe
Journal:  Am J Hypertens       Date:  2019-01-15       Impact factor: 2.689

8.  Mineralocorticoid Receptor in Smooth Muscle Contributes to Pressure Overload-Induced Heart Failure.

Authors:  Seung Kyum Kim; Lauren A Biwer; M Elizabeth Moss; Joshua J Man; Mark J Aronovitz; Gregory L Martin; Francisco J Carrillo-Salinas; Ane M Salvador; Pilar Alcaide; Iris Z Jaffe
Journal:  Circ Heart Fail       Date:  2021-02-01       Impact factor: 8.790

9.  Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A.

Authors:  Jean-Philippe Bertocchio; Coralie Barbe; Sylvie Lavaud; Olivier Toupance; Pierre Nazeyrollas; Frederic Jaisser; Philippe Rieu
Journal:  PLoS One       Date:  2016-04-18       Impact factor: 3.240

Review 10.  The Mineralocorticoid Receptor in Salt-Sensitive Hypertension and Renal Injury.

Authors:  Nobuhiro Ayuzawa; Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2021-01-04       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.